Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations

DOI: https://doi.org/10.2147/DMSO.S331654

2022-02-04

Abstract:David M Williams, 1 Hannah Jones, 1 Jeffrey W Stephens 1, 2 1 Department of Diabetes and Endocrinology, Morriston Hospital, Swansea Bay University Health Board, Swansea, SA6 8NL, UK; 2 Diabetes Research Group, Swansea University Medical School, Swansea University, Swansea, SA2 8PP, UK Correspondence: David M Williams Diabetes Centre, Morriston Hospital, Swansea, SA6 6NL., UK, Tel +441792704078, Email Previous guidelines for the treatment of people with type 2 diabetes mellitus (T2D) have relied heavily upon rigid algorithms for the sequential addition of pharmacotherapies to achieve target glycemic control. More recent guidelines advocate a personalized approach for diabetes treatment, to improve patient satisfaction, quality of life, medication adherence and overall health outcomes. Clinicians should work with patients to develop personalized goals for their treatment, including targeted glycemic control, weight management, prevention and treatment of associated comorbidities and avoidance of complications such as hypoglycemia. Factors that affect the intensity of treatment and choice of pharmacotherapy should include medical and patient influences. Medical considerations include the diabetes phenotype, biomarkers including genetic tests, and the presence of comorbidities such as cardiovascular, renal, or hepatic disease. Patient factors include their treatment preference, age and life expectancy, diabetes duration, hypoglycemia fear and unawareness, psychological and social circumstances. The use of a personalized approach in the management of people with T2D can reduce the cost and failure associated with the algorithmic "one-size-fits-all" approach, to anticipate disease progression, improve the response to diabetes pharmacotherapy and reduce the incidence of diabetes-associated complications. Ultimately, the use of personalized medicine in people with T2D should improve medication adherence, patient satisfaction and quality of life to reduce diabetes distress and improve physical health outcomes. Keywords: type 2 diabetes mellitus, personalized management, precision medicine, resources, treatment Currently, the management of type 2 diabetes (T2D) is driven by established international guidelines, and until recent years these did not take account of individual characteristics and the presence of co-morbidities for individual patients. Much of the treatment options recommended by guidelines are based on evidence accumulated from Phase 3 clinical trials and real-world evidence based on population-based studies. These recommendations have clearly made a difference to overall diabetes care. 1,2 These guidelines do not examine the concept of individualized or personalized management. Individuals differ in their presentation of T2D, some have a short duration, others a long duration and other complications at the time of presentation. Therefore, with respect to treatment, "one size does not fit all". More recently, the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) (along with other guidelines) have recommended tailoring therapy to be more stringent and less stringent based on patients' attitudes, hypoglycemia risk, disease duration, life expectancy, comorbidities and resources. 3 Personalized diabetes management is based on developing a clinical plan that is tailored to the individual. This may take into account many complex factors. These included patient factors, social, medical (including complications) as well as phenotypic, biochemical and genetic factors (see Figure 1). Therefore, the concept of personalized management is complex and broad. The therapeutic options for managing T2D have increased considerably in the past 10 years, so perhaps the time has come to focus and tailor therapy to the phenotype and personal characteristics of the patient. Personalized care may provide the opportunity to address two potential reasons for the continued morbidity and mortality associated with T2D. These include firstly, the suboptimal application of evidence-based therapies (eg, due to lack of medication intensification or insufficient lifestyle changes or medication adherence by patients) and secondly inadequate efficacies of current therapies when optimally applied. 4 Figure 1 Personalized diabetes care. This figure summarizes the key considerations that are needed when contemplating the choice of diabetes pharmacotherapy for a patient with T2D. It may be argued that personalized diabetes care has been practiced for many years, 5 but the complexity of integrating this into the routine management of T2D remains a challenge with many barriers. 6 To date there are few studies, which have examined the effects of personalized care on diab -Abstract Truncated-